Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$24.52 USD
-0.54 (-2.15%)
Updated May 3, 2024 04:00 PM ET
After-Market: $25.00 +0.48 (1.96%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 368 | 432 | 224 | 441 | 276 |
Receivables | 41 | 31 | 28 | 26 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 6 | 5 | 5 | 5 |
Other Current Assets | 42 | 30 | 10 | 7 | 6 |
Total Current Assets | 459 | 499 | 266 | 479 | 307 |
Net Property & Equipment | 0 | 1 | 1 | 2 | 1 |
Investments & Advances | 57 | 5 | 112 | 36 | 39 |
Other Non-Current Assets | 8 | 11 | 13 | 16 | 12 |
Deferred Charges | 91 | 61 | 27 | 32 | 46 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 5 | 3 | 5 | 3 |
Total Assets | 622 | 583 | 424 | 572 | 412 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 12 | 7 | 11 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 87 | 45 | 40 | 35 | 30 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 14 | 0 | 0 | 2 |
Total Current Liabilities | 105 | 72 | 48 | 47 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 10 | 9 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 115 | 82 | 48 | 48 | 41 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 739 | 662 | 591 | 516 | 457 |
Retained Earnings | 403 | 296 | 195 | 82 | -24 |
Other Equity | 1 | -1 | 0 | 0 | 0 |
Treasury Stock | 635 | 456 | 410 | 76 | 63 |
Total Shareholder's Equity | 507 | 502 | 376 | 523 | 371 |
Total Liabilities & Shareholder's Equity | 622 | 583 | 424 | 572 | 412 |
Total Common Equity | 507 | 502 | 376 | 523 | 371 |
Shares Outstanding | 103.00 | 107.60 | 115.40 | 116.10 | 114.20 |
Book Value Per Share | 4.92 | 4.66 | 3.26 | 4.51 | 3.25 |
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 368 | 355 | 363 | 465 |
Receivables | NA | 41 | 35 | 33 | 33 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 8 | 8 | 7 | 6 |
Other Current Assets | NA | 42 | 34 | 30 | 30 |
Total Current Assets | NA | 459 | 432 | 433 | 534 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 57 | 60 | 0 | 0 |
Other Non-Current Assets | NA | 8 | 9 | 9 | 10 |
Deferred Charges | NA | 91 | 87 | 78 | 68 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 7 | 7 | 4 | 5 |
Total Assets | NA | 622 | 594 | 525 | 618 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 17 | 17 | 8 | 11 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 87 | 91 | 71 | 53 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 14 | 14 | 14 |
Total Current Liabilities | NA | 105 | 122 | 93 | 79 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 10 | 10 | 10 | 9 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 115 | 132 | 103 | 88 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 739 | 722 | 696 | 680 |
Retained Earnings | NA | 403 | 371 | 340 | 312 |
Other Equity | NA | 1 | 0 | 0 | 0 |
Treasury Stock | NA | 635 | 632 | 614 | 463 |
Total Shareholder's Equity | NA | 507 | 462 | 422 | 530 |
Total Liabilities & Shareholder's Equity | NA | 622 | 594 | 525 | 618 |
Total Common Equity | 0 | 507 | 462 | 422 | 530 |
Shares Outstanding | 103.50 | 103.00 | 103.00 | 102.50 | 101.50 |
Book Value Per Share | 0.00 | 4.92 | 4.48 | 4.11 | 5.22 |